N/A
Completed N=181
ROSA Robot Used in Total Knee Replacement Post Market Study
Postoperative Pain · Chronic Osteoarthritis · Avascular Necrosis of the Femoral Condyle · Moderate Varus, Valgus or Flexion Deformities
Source: ClinicalTrials.gov NCT03969654 ↗
Enrolled (actual)
181
Serious AEs
4.4%
Results posted
May 2024
Primary outcomePrimary: Clinical Performance — .540; .442; .740; .763 score on a scale
Summary
This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of workflow efficiency, patient pain and function, and adverse event data. This clinical study will include Persona, NexGen, and Vanguard product families using the ROSA Total Knee Robotic System or conventional instrumentation. The primary objective of this study is to collect and compare clinical and surgical data using the commercially available ROSA Total Knee robotic instrumentation and conventional instrumentation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Performance |
.540; .442; .740; .763; .826; .842 | — |
| PRIMARY Oxford |
24.6; 22.2; 32.0; 32.5; 38.2; 38.5 | — |
| PRIMARY Post-Operative Pain & Satisfaction |
80; 32; 32; 9; 12; 2 | — |
| PRIMARY Total Range of Motion |
121.0; 115.7; 114.5; 111.4; 121.1; 120.7 | — |
Eligibility Criteria
Inclusion Criteria
- Patient is a minimum of 18 years of age
- Independent of study participation, patient is a candidate for commercially available Persona, NexGen, and Vanguard knee components implanted in accordance with product labeling
- Patient has participated in this study-related Informed Consent process
- Patient is willing and able to provide written Informed Consent by signing and dating the IRB or EC approved Informed Consent form
- Patient is willing and able to complete scheduled study procedures and follow-up evaluations
Exclusion Criteria
- Patient is currently participating in any other surgical intervention studies or pain management studies
- Patient has underwent contralateral UKA or TKA within the last 18 months
- Hip pathology with significant bone loss (e.g. avascular necrosis of the femoral head with collapse, severe dysplasia of the femoral head or the acetabulum)
- Hip pathology severely limiting range of motion (e.g. arthrodesis, severe contracture, chronic severe dislocation)
- Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.)
- Patient has previously received partial or total knee arthroplasty for the ipsilateral knee
Data sourced from ClinicalTrials.gov (NCT03969654). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.